Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Short term Debt (2016 - 2022)

Acro Biomedical has reported Short term Debt over the past 7 years, most recently at $78826.0 for Q4 2022.

  • Quarterly results put Short term Debt at $78826.0 for Q4 2022, up 280.05% from a year ago — trailing twelve months through Dec 2022 was $78826.0 (up 280.05% YoY), and the annual figure for FY2022 was $78826.0, up 280.05%.
  • Short term Debt for Q4 2022 was $78826.0 at Acro Biomedical, roughly flat from $78594.0 in the prior quarter.
  • Over the last five years, Short term Debt for ACBM hit a ceiling of $257567.0 in Q1 2021 and a floor of $3266.0 in Q4 2018.
  • Median Short term Debt over the past 5 years was $70306.0 (2020), compared with a mean of $86005.2.
  • Peak annual rise in Short term Debt hit 994.08% in 2018, while the deepest fall reached 92.11% in 2018.
  • Acro Biomedical's Short term Debt stood at $3266.0 in 2018, then soared by 704.62% to $26279.0 in 2019, then skyrocketed by 824.51% to $242951.0 in 2020, then crashed by 91.46% to $20741.0 in 2021, then soared by 280.05% to $78826.0 in 2022.
  • The last three reported values for Short term Debt were $78826.0 (Q4 2022), $78594.0 (Q3 2022), and $21245.0 (Q2 2022) per Business Quant data.